| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.017 | 0.7 |
| mRNA | UNC0321 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.018 | 0.7 |
| mRNA | NU-7441 | GDSC1000 | pan-cancer | AAC | 0.012 | 0.7 |
| mRNA | CX-5461 | GDSC1000 | pan-cancer | AAC | 0.011 | 0.7 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.017 | 0.8 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | -0.025 | 0.8 |